- Barrons.com•14 hours ago
In a report looking ahead to earnings from specialty pharmaceutical companies like Allergan (AGN), and Endo International (ENDP), JPMorgan's Chris Schott and team call Valeant Pharmaceuticals International (VRX) a name to "avoid." They explain why: Ahead of 3Q EPS results, we wanted to share our latest thoughts on our Specialty Pharma group. For names we would own into 3Q, we would highlight Allergan, Endo International and Akorn (AKRX) and would avoid Valeant and Impax Laboratories (IPXL), where we see risk to guidance given the implied steep 2H ramp... Valeant: Remain cautious into a widely expected guidance cut.
- Investopedia•4 days ago
Akorn Inc. was slapped with a warning letter after the FDA found 6 quality-control violations at its Decatur, Illinois, drug manufacturing plant.
- GlobeNewswire•12 days ago
LAKE FOREST, Ill., Oct. 13, 2016-- Akorn, Inc., a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on Thursday, November 3, 2016 outlining the third ...
Akorn, Inc. (AKRX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Day's Range||26.20 - 27.00|
|52wk Range||17.57 - 39.46|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.68|
|Avg Vol (3m)||1,183,360|
|Dividend & Yield||0.00 (0.00%)|